Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivationAssociations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly intervention